Nephrol Dial Transplant (2001) 16: 1545-1549
© 2001 European Renal Association-European Dialysis and Transplant Association
Editorial Comments
Causes of death after renal transplantation
Chairman, ERA–EDTA Registry, Academic Medical Centre, Amsterdam, The Netherlands
Keywords: renal transplantation; mortality; cardiovascular disease; malignancy; infection
Introduction
The survival of patients who undergo renal transplantation has improved considerably over the past three decades. At present one can expect a survival rate of 95% at 1 year and around 90% at 3–5 years. The risk of death has fallen over the years in all categories of patients but this is evident especially in the older age groups and in those with considerable comorbid disease such as many of the patients with diabetes mellitus. For example, in the mid 1970s 1-year patient survival in those over 35 years of age was only around 60% while in the younger adult it was around 85%. By the 1990s the difference had narrowed to just over 5% with 1-year survival at or just below 90% for older patients and at or just above 95% for younger adult recipients. Thus in the short term, renal transplantation now offers a good prospect of survival
Causes of death
Cardiovascular disease
Malignancy
Infection
Miscellaneous causes of death
Conclusions
Notes
References
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J Galliford and D S Game Modern renal transplantation: present challenges and future prospects Postgrad. Med. J., February 1, 2009; 85(1000): 91 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Chapman and J. M. Campistol Malignancy in renal transplantation: opportunities with proliferation signal inhibitors: Guest editors' introduction Nephrol. Dial. Transplant., May 1, 2007; 22(suppl_1): i1 - i3. [Full Text] [PDF]
|
|
|
|
|
|
J. Dantal and E. Pohanka Malignancies in renal transplantation: an unmet medical need Nephrol. Dial. Transplant., May 1, 2007; 22(suppl_1): i4 - i10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Campistol, J. Albanell, W. Arns, I. Boletis, J. Dantal, J. W. de Fijter, S. A. Mortensen, H.-H. Neumayer, O. Oyen, J. Pascual, et al. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance Nephrol. Dial. Transplant., May 1, 2007; 22(suppl_1): i36 - i41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Djamali, M. Samaniego, B. Muth, R. Muehrer, R. M. Hofmann, J. Pirsch, A. Howard, G. Mourad, and B. N. Becker Medical Care of Kidney Transplant Recipients after the First Posttransplant Year Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 623 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Deb, C. J. Mullany, P. S. Kamath, J. A. Dearani, R. C. Daly, T. A. Orszulak, and H. V. Schaff Cardiac Surgery in Kidney and Liver Transplant Recipients Mayo Clin. Proc., July 1, 2006; 81(7): 917 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Holdaas, B. Fellstrom, A. G. Jardine, G. Nyberg, C. Gronhagen-Riska, S. Madsen, H.-H. Neumayer, E. Cole, B. Maes, P. Ambuhl, et al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation Nephrol. Dial. Transplant., May 1, 2005; 20(5): 974 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Magee and M. Pascual Update in Renal Transplantation Arch Intern Med, July 12, 2004; 164(13): 1373 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Morath, M. Mueller, H. Goldschmidt, V. Schwenger, G. Opelz, and M. Zeier Malignancy in Renal Transplantation J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1582 - 1588. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Ballantyne, A. Corsini, M. H. Davidson, H. Holdaas, T. A. Jacobson, E. Leitersdorf, W. Marz, J. P. D. Reckless, and E. A. Stein Risk for Myopathy With Statin Therapy in High-Risk Patients Arch Intern Med, March 10, 2003; 163(5): 553 - 564. [Abstract] [Full Text] [PDF]
|
|